Blackstone Inc’s Indivior Pharmaceuticals INDV Stock Holding History

Blackstone Inc’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-42,288	Closed	-$1.52M	–	455
2025 Q4	$1.52M	Buy	+42,288	New	+$1.29M	0.01%	206

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Blackstone Inc's INDV Position: Q1 2026 in Review

Blackstone Inc sold out of Indivior Pharmaceuticals (INDV) in Q1 2026, closing a stake of 42,288 shares — an estimated $1.52M sold.

Blackstone Inc first reported a position in INDV in Q4 2025 and held it in 1 quarter. The position peaked at $1.52M in Q4 2025. 290 funds tracked by Wall St. Rank hold INDV as of Q1 2026.

Blackstone Inc reported no remaining Indivior Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Blackstone Inc sold 42,288 Indivior Pharmaceuticals shares in Q1 2026, an estimated $1.52M.
Blackstone Inc first reported a position in Indivior Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Blackstone Inc's Indivior Pharmaceuticals position peaked at $1.52M in Q4 2025.
290 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q1 2026.

Based on Blackstone Inc's 13F filing for Q1 2026, filed 15 May 2026.